Therefore, understanding the processes that control upregulation of Bcl-XL in response to microenvironmental stimuli is clinically relevant and may identify novel targets or approaches for therapy of CLL. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.